Organogenesis Holdings Inc. Files 8-K for Material Definitive Agreement

TL;DR

Organogenesis (ORGO) filed an 8-K on 11/18/24 for a material definitive agreement.

AI Summary

Organogenesis Holdings Inc. announced on November 18, 2024, that it entered into a Material Definitive Agreement. The company, formerly known as Avista Healthcare Public Acquisition Corp., is incorporated in Delaware and headquartered in Canton, MA. This filing is a current report under Section 13 or 15(d) of the Securities Exchange Act of 1934.

Why It Matters

This filing indicates a significant new agreement for Organogenesis Holdings Inc., which could impact its business operations, financial performance, and strategic direction.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks or opportunities that may affect the company's future performance and stock price.

Key Numbers

• 001-37906 — SEC File Number (Identifies the company's filing with the SEC.)
• 98-1329150 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• Organogenesis Holdings Inc. (company) — Registrant
• November 18, 2024 (date) — Date of Earliest Event Reported
• Avista Healthcare Public Acquisition Corp. (company) — Former Company Name
• Delaware (jurisdiction) — State of Incorporation
• Canton, MA (location) — Principal Executive Offices
• Securities Exchange Act of 1934 (legal_document) — Governing Act

FAQ

Key Financial Figures

• $0.0001 — hich registered Class A Common Stock, $0.0001 par value ORGO Nasdaq Capital Marke
• $43.00 — he Company will pay annual base rent of $43.00 per square foot commencing June 1, 2026
• $1,250,000 — case the Company must pay the Landlord $1,250,000 if it so terminates. The Company plan

Filing Documents

• orgo-20241118.htm (8-K) — 50KB
• orgo-ex99_1.htm (EX-99.1) — 10KB
• img36819578_0.jpg (GRAPHIC) — 1KB
• 0000950170-24-130202.txt ( ) — 179KB
• orgo-20241118.xsd (EX-101.SCH) — 29KB
• orgo-20241118_htm.xml (XML) — 4KB

01. Entry into a Material Definitive Agreement

Item 1.01. Entry into a Material Definitive Agreement. On November 18, 2024, Organogenesis Holdings Inc. and its wholly-owned subsidiary Organogenesis Inc. (together, the "Company") entered into a lease (the "Lease") with DIV Technology Way, LLC (the "Landlord"). Under the Lease, the Company is leasing from the Landlord approximately 122,000 square feet of space at 100 Technology Way, Smithfield, Rhode Island (the "Premises"). The Company intends to build out the Premises and use the Premises to manufacture certain of its products. The Company is obligated under the Lease to complete its build out of the Premises within 36 months of the Lease commencement. The Company will receive from the Landlord an allowance to offset partially the cost of its build out. The initial term of the Lease is approximately sixteen and one-half years commencing November 18, 2024 and expiring May 31, 2041. The Company has two ten-year renewal options. After a period of no or reduced rent, the Company will pay annual base rent of $43.00 per square foot commencing June 1, 2026. The annual base rent increases by 3% each year thereafter during the initial term of the Lease. The Lease is triple net, meaning that in addition to the base annual rent, the Company is responsible for real estate taxes and operating expenses with respect to the Premises. The Company has a one-time right of first offer to purchase the Premises. The Company has a right to terminate the Lease if the Company has not secured certain anticipated state and local tax incentives by March 31, 2025, in which case the Company must pay the Landlord $1,250,000 if it so terminates. The Company plans to file the Lease as an Exhibit to its Annual Report on Form 10-K for the year ended December 31, 2024.

01 Other Events

Item 8.01 Other Events. On November 22, 2024, Organogenesis Holdings Inc. issued a press release announcing that it entered into the Lease, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements that relate to expectations or forecasts of future events. Forward-looking statements may be identified by the use of words such as "future," "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements with respect to the operations of the Company, strategies, prospects, and other aspects of the business of the Company are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. These factors include, but are not limited to: (1) the impact of any changes to the coverage and reimbursement levels for the Company's products (including as a result of recent LCDs or any changes to those LCDs); (2) the Company faces significant and continuing competition, which could adversely affect its business, results of operations and financial condition; (3) rapid technological change could cause the Company's products to become obsolete and if the Company does not enhance its product offerings through its research and development efforts, it may be unable to effectively compete; (4) to be commercially successful, the Company must convince physicians that its products are safe and effective alternatives to existing treatments and that its products should be used in their procedures; (5) the Company has incurred losses in the current period and prior periods and may incur losses in the future; (6) changes in applicable laws or regulations; (7) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; (8) the Company's ability to maintain producti

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated November 22, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Organogenesis Holdings Inc. By: /s/ Lori Freedman Name: Lori Freedman Title: Chief Administrative and Legal Officer Date: November 22, 2024

View Full Filing

View this 8-K filing on SEC EDGAR